Orthopedic Regenerative Medicine Market, By Type (Stem Cell, Biomaterial and Tissue Engineering), By Application (Osteoarticular Diseases, Rheumatoid Arthritis, Ligament Injuries, Burisitis, Osteoporosis and Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023

Code : CMI4841

Pages :180

Formats :

Excel and PDF

Industry : Biotechnology

Market News

Global Orthopedic Regenerative Medicine Market: Key Developments

On April 3, 2023, Jaslok Hospital, a private hospital located in Mumbai, India, announced the launch of the first restorative and regenerative department in India for complex treatments. The department will offer non-invasive neuromodulation treatment for psychiatric disease and chronic pain in neurological conditions. It will also provide ortho biologics for various cell-based treatments for bone and joint disorders and platelet-rich plasma for orthopedic, vascular, and cosmetic therapies.
On June 6, 2023, Biocomposites, a developer and distributor of calcium compound devices that regenerate and repair bone and soft tissue, announced the acquisition of Artoss, a company that provides a range of bone graft substitute products. This acquisition will expand Biocomposites’ product portfolio.
In November 2020, OssDsign, an innovator, designer, and manufacturer of personalized bone replacement technology for cranial repair, announced the acquisition of Sirakoss, a medical device company. Sirakoss is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The Sirakoss bone graft substitutes uses advanced technology to catalyze faster bone regeneration coupled with total graft resorption. This acquisition will expand OssDsign’s product portfolio.
In October 2022, Orthofix, a global medical device company with focus on spine and orthopedics, and SeaSpine, a global medical technology company that focuses on surgical solutions for the treatment of spinal disorders, announced they both had entered into a definitive agreement to combine in an all-stock merger of equals. The combined company, to be named prior to the transaction’s closing, will be a leading global spine and orthopedics company with highly complementary portfolios of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system.